The multifunctional role of Notch signaling in multiple myeloma
- PMID: 34778567
- PMCID: PMC8589324
- DOI: 10.20517/2394-4722.2021.35
The multifunctional role of Notch signaling in multiple myeloma
Abstract
Multiple myeloma (MM) is a hematologic cancer characterized by uncontrolled growth of malignant plasma cells in the bone marrow and currently is incurable. The bone marrow microenvironment plays a critical role in MM. MM cells reside in specialized niches where they interact with multiple marrow cell types, transforming the bone/bone marrow compartment into an ideal microenvironment for the migration, proliferation, and survival of MM cells. In addition, MM cells interact with bone cells to stimulate bone destruction and promote the development of bone lesions that rarely heal. In this review, we discuss how Notch signals facilitate the communication between adjacent MM cells and between MM cells and bone/bone marrow cells and shape the microenvironment to favor MM progression and bone disease. We also address the potential and therapeutic approaches used to target Notch signaling in MM.
Keywords: Notch; bone; multiple myeloma; osteoblasts; osteoclasts; osteocytes; tumor microenvironment; γ-secretase inhibitors.
Conflict of interest statement
Conflicts of interest All authors declared that there are no conflicts of interest.
Figures


Similar articles
-
Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.Cancer Res. 2016 Mar 1;76(5):1089-100. doi: 10.1158/0008-5472.CAN-15-1703. Epub 2016 Feb 1. Cancer Res. 2016. PMID: 26833121 Free PMC article.
-
Pathogenesis and treatment of multiple myeloma bone disease.Jpn Dent Sci Rev. 2021 Nov;57:164-173. doi: 10.1016/j.jdsr.2021.08.006. Epub 2021 Sep 23. Jpn Dent Sci Rev. 2021. PMID: 34611468 Free PMC article. Review.
-
The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.Int J Mol Sci. 2021 Apr 24;22(9):4462. doi: 10.3390/ijms22094462. Int J Mol Sci. 2021. PMID: 33923357 Free PMC article. Review.
-
Myeloma-Bone Interaction: A Vicious Cycle via TAK1-PIM2 Signaling.Cancers (Basel). 2021 Sep 3;13(17):4441. doi: 10.3390/cancers13174441. Cancers (Basel). 2021. PMID: 34503251 Free PMC article. Review.
-
Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.Dan Med Bull. 2011 May;58(5):B4277. Dan Med Bull. 2011. PMID: 21535989 Review.
Cited by
-
Molecular and immunological mechanisms of clonal evolution in multiple myeloma.Front Immunol. 2023 Sep 6;14:1243997. doi: 10.3389/fimmu.2023.1243997. eCollection 2023. Front Immunol. 2023. PMID: 37744361 Free PMC article. Review.
-
Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance.Blood Cancer J. 2024 Aug 20;14(1):140. doi: 10.1038/s41408-024-01121-8. Blood Cancer J. 2024. PMID: 39164264 Free PMC article.
-
Updates on CAR T cell therapy in multiple myeloma.Biomark Res. 2024 Sep 12;12(1):102. doi: 10.1186/s40364-024-00634-5. Biomark Res. 2024. PMID: 39261906 Free PMC article. Review.
-
The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma.Int J Mol Sci. 2023 Sep 26;24(19):14558. doi: 10.3390/ijms241914558. Int J Mol Sci. 2023. PMID: 37834003 Free PMC article.
-
Hypermethylation of the Promoter Region of miR-23 Enhances the Metastasis and Proliferation of Multiple Myeloma Cells via the Aberrant Expression of uPA.Front Oncol. 2022 May 30;12:835299. doi: 10.3389/fonc.2022.835299. eCollection 2022. Front Oncol. 2022. PMID: 35707350 Free PMC article.
References
Grants and funding
LinkOut - more resources
Full Text Sources